Overall, it clearly emerges from our study that, upon TLR triggering, high proportions of CD40/CD86‐expressing DCs were mainly linked to a better clinical outcome in the circulation but mostly associated with worse prognosis in the tumor, whereas high levels of both circulating and tumor‐infiltrating cytokine‐producing DCs were generally connected to a better clinical outcome. The gene discussed is CD40; the disease is neoplasm.